Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6)

Manuel Santamaria, Olaf Neth, Jo A. Douglass, Gergely Krivan, Robin Kobbe, Ewa Bernatowska, Sofia Grigoriadou, Claire Bethune, Anita Chandra, Gerd Horneff, Michael Borte, Anja Sonnenschein, Pavlina Kralickova, Silvia Sánchez Ramón, Daman D. Langguth, Luis Ignacio Gonzalez‑Granado, Laia Alsina*, Montse Querolt, Rhonda Griffin, Carrie HamesElsa Mondou, Jeffrey Price, Ana Sanz, Jiang Lin

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency (Journal of Clinical Immunology, (2022), 42, 3, (500-511), 10.1007/s10875-021-01181-6)'. Together they form a unique fingerprint.

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science